1. Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1H)-one Derivatives as Orally eIF4A3-Selective Inhibitors
- Author
-
Douglas R. Cary, Ryosuke Arai, Daisuke Morishita, Junpei Takeda, Shinobu Sasaki, Ryo Mizojiri, Sachio Shibata, Koichiro Fukuda, Misa Iwatani-Yoshihara, Mai Kosaka, Yohei Kosugi, Yoshihiko Satoh, Daisuke Nakata, Masahiro Kamaura, Kazuaki Takami, Yasuhiro Imaeda, and Shigekazu Sasaki
- Subjects
0301 basic medicine ,Stereochemistry ,Organic Chemistry ,Metabolic stability ,Body weight ,Biochemistry ,Bioavailability ,03 medical and health sciences ,Inhibitory potency ,Piperazine ,chemistry.chemical_compound ,030104 developmental biology ,chemistry ,In vivo ,Drug Discovery ,Molecule - Abstract
Starting from our previous eIF4A3-selective inhibitor 1a, a novel series of (piperazine-1-carbonyl)pyridin-2(1H)-one derivatives was designed, synthesized, and evaluated for identification of orally bioavailable probe molecules. Compounds 1o and 1q showed improved physicochemical and ADMET profiles, while maintaining potent and subtype-selective eIF4A3 inhibitory potency. In accord with their promising PK profiles and results from initial in vivo PD studies, compounds 1o and 1q showed antitumor efficacy with T/C values of 54% and 29%, respectively, without severe body weight loss. Thus, our novel series of compounds represents promising probe molecules for the in vivo pharmacological study of selective eIF4A3 inhibition.
- Published
- 2017